KMDA vs. PRTK, FULC, BYSI, UBX, CTIC, COLL, CALT, ARQT, EVO, and GYRE
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Paratek Pharmaceuticals (PRTK), Fulcrum Therapeutics (FULC), BeyondSpring (BYSI), Unity Biotechnology (UBX), CTI BioPharma (CTIC), Collegium Pharmaceutical (COLL), Calliditas Therapeutics AB (publ) (CALT), Arcutis Biotherapeutics (ARQT), Evotec (EVO), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
Paratek Pharmaceuticals (NASDAQ:PRTK) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
53.6% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 8.0% of Paratek Pharmaceuticals shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Kamada has a net margin of 9.75% compared to Paratek Pharmaceuticals' net margin of -35.44%. Kamada's return on equity of 6.15% beat Paratek Pharmaceuticals' return on equity.
Paratek Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Paratek Pharmaceuticals received 113 more outperform votes than Kamada when rated by MarketBeat users. However, 65.84% of users gave Kamada an outperform vote while only 61.33% of users gave Paratek Pharmaceuticals an outperform vote.
Kamada has a consensus price target of $14.50, suggesting a potential upside of 171.03%. Given Kamada's higher probable upside, analysts clearly believe Kamada is more favorable than Paratek Pharmaceuticals.
Kamada has lower revenue, but higher earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kamada had 1 more articles in the media than Paratek Pharmaceuticals. MarketBeat recorded 1 mentions for Kamada and 0 mentions for Paratek Pharmaceuticals. Kamada's average media sentiment score of 0.59 beat Paratek Pharmaceuticals' score of 0.00 indicating that Kamada is being referred to more favorably in the news media.
Summary
Kamada beats Paratek Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
